Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Should You Sell?

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.82 and traded as low as $3.48. Cryo-Cell International shares last traded at $3.64, with a volume of 7,996 shares changing hands.

Cryo-Cell International Price Performance

The stock has a market cap of $29.34 million, a price-to-earnings ratio of -11.74 and a beta of 0.54. The firm has a fifty day moving average of $3.30 and a 200 day moving average of $3.82.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.47) earnings per share for the quarter. The business had revenue of $7.84 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission (SEC). 10.44% of the stock is currently owned by hedge funds and other institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.